Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 17/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923481 | 0.88 | P2RX7 (1.00) | P2RX7SMN1; SMN2 | |
| SCHEMBL15914279 | 0.81 | SMN1; SMN2 (1.00) | P2RX7SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL1199009 | 0.81 | P2RX7 (1.00) | P2RX7P2RX3 | |
| SCHEMBL4512928 | 0.81 | P2RX7 (0.60) | P2RX7SMN1; SMN2 | |
| SCHEMBL6618315 | 0.81 | P2RX7 (0.66) | P2RX7P2RX3 | |
| SCHEMBL4505239 | 0.81 | P2RX7 (0.63) | P2RX7P2RX3 | |
| SCHEMBL4501549 | 0.81 | P2RX7 (0.59) | P2RX7SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5923993 | 0.80 | P2RX7 (0.80) | P2RX7SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL14583955 | 0.79 | P2RX7 (0.61) | P2RX7SMN1; SMN2ALDH1A1LMNAHTT | |
| SCHEMBL4508579 | 0.78 | MEN1 (0.61) | P2RX7P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | claimed |
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | claimed |
| JP-2007501782-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654217-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | claimed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | claimed |
| WO-2005014529-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | claimed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | claimed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-1654217-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | AstraZeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| WO-2005014529-A1 | 2- ADAMANTYL DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS. | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037830-A1 | 2-Adamantyl derivatives as p2X7 receptor antagonists. | P2RX2, P2RX3, P2RX7 | P2RX7 3/4885SMN1; SMN2 3272/4885ALDH1A1 2254/4885 |
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 554/4885SMN1; SMN2 718/4885ALDH1A1 117/4885 |
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 732/4885SMN1; SMN2 626/4885ALDH1A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.